SCHEMBL16248352

SCHEMBL16248352

[2H]c1c([2H])c(N(CC)C(=O)c2c(O)c3c(Cl)cccc3n(C)c2=O)c([2H])c([2H])c1C

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 1/20 0.39
MEN1 O00255 7/20 0.38
KMT2A Q03164 7/20 0.38
PGR P06401 1/20 0.38
NPC1 O15118 3/20 0.37
ALDH1A1 P00352 3/20 0.36
KDM4E B2RXH2 1/20 0.36
EGFR P00533 1/20 0.36
TP53 P04637 1/20 0.36
POLB P06746 1/20 0.35
PABPC1 P11940 1/20 0.35
RAB9A P51151 1/20 0.35
MAPT P10636 1/20 0.35
TAS2R14 Q9NYV8 1/20 0.35
GPBAR1 Q8TDU6 2/20 0.34
RORC P51449 1/20 0.34
ALOX15 P16050 1/20 0.33
CNR2 P34972 1/20 0.33
NLRP3 Q96P20 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Laquinimod SCHEMBL889435 0.91 HDAC4 (0.39) HDAC4MEN1KMT2APGRNPC1
SCHEMBL7538318 0.90 HDAC4 (0.43) HDAC4MEN1KMT2APGRNPC1
SCHEMBL16248355 0.89 HDAC4 (0.37) HDAC4MEN1KMT2APGRNPC1
SCHEMBL889434 0.89 HDAC4 (0.37) HDAC4MEN1KMT2APGRNPC1
Laquinimod SCHEMBL39440 0.86 TP53 (0.50) HDAC4MEN1KMT2APGRNPC1
Laquinimod SCHEMBL29438575 0.86 TP53 (0.50) HDAC4MEN1KMT2APGRNPC1
SCHEMBL23531675 0.85 HDAC4 (0.43) HDAC4MEN1KMT2APGRNPC1
Laquinimod SCHEMBL1573491 0.85 TP53 (0.49) HDAC4MEN1KMT2APGRNPC1
SCHEMBL7537578 0.85 CYP3A4 (0.45) HDAC4MEN1KMT2APGRNPC1
Laquinimod SCHEMBL1573702 0.85 TP53 (0.49) HDAC4MEN1KMT2APGRNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9102620-B2 Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 2015-08-11 US disclosed
US-20140343096-A1 DEUTERATED N-ETHYL-N-PHENYL-1,2-DIHYDRO-4-HYDROXY-5-CHLORO-1-METHYL-2-OXOQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 2014-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343096-A1 DEUTERATED N-ETHYL-N-PHENYL-1,2-DIHYDRO-4-HYDROXY-5-CHLORO-1-METHYL-2-OXOQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF HDHD5, DDAH1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 HDAC4 445/4885MEN1 1098/4885KMT2A 209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.